Skip to main content

Agilent s eArray 3.0 and Whole Rat Genome Oligo Microarray and Genpathway s TranscriptionPath, FactorPath, and PromoterPath

Premium

Agilent said this week that it has launched eArray 3.0, a web portal that allows researchers to design custom microarrays for drug discovery, disease studies, and basic research.

The portal provides access to Agilent’s genomic content, annotation information, and probe sequences, and enables users to design custom microarrays using Agilent probes, probes from their own sources, or a combination of both. Once the full complement of probes has been selected, customers can compose the microarray using various layouts.

The tool is free and available at http://earray.chem.agilent.com/earray/login.do.

Agilent also said this week that it has introduced the Whole Rat Genome Oligo Microarray.

With probes for more than 41,000 unique genes and transcripts, the oligonucleotide microarray provides the broad genome coverage, validated genomic content, and sensitivity to assess the effect of environmental toxins or drug interactions on cells, said Agilent.

Each microarray features highly sensitive 60-mer oligonucleotide probes, which allow increased detection of low-expressing genes.


Genpathway said this week that it has introduced TranscriptionPath, FactorPath, and PromoterPath, three tools for the discovery and characterization of differential gene transcription, components and processes for gene regulation, and corresponding genetic pathways.

TranscriptionPath allows for the identification and quantitation of gene transcription based on isolation and haracterization of DNA/transcription machinery complexes.

FactorPath allows for the discovery and quantitation of binding by transcription factors and coactivators.

PromoterPath allows for the identification of promoters and enhancers, and quantitation of their use.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.